Relevance of the Processed Blood Volume per Granulocyte and Monocyte Apheresis Session to its Clinical Efficacy in Patients With Ulcerative Colitis

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 4, 2011, Pages 360-366

  Kikuyama, Risa ^a,c   Fukunaga, Ken ^a   Kawai, Mikio ^a   Yokoyama, Yoko ^a   Kamikozuru, Koji ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Takeda, Naohisa ^a   Yoshida, Koji ^a   Iimuro, Masaki ^a   Kato, Kyoichi ^a   Kono, Tomoaki ^a   Nogami, Koji ^a   Nagase, Kazuko ^a   Nakamura, Shiro ^a   Takei, Yoshiyuki ^c   Miwa, Hiroto ^b   Matsumoto, Takayuki ^a  

^a Divisions of Lower Gastroenterology   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adsorptive granulocyte monocyte apheresis; Bodyweight; Inflammatory bowel diseases; Processed blood volume; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BLOOD VOLUME; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GRANULOCYTE; GRANULOCYTE MONOCYTE ADSORPTION; HUMAN; MALE; PRIORITY JOURNAL; PROCESSED BLOOD VOLUME; REMISSION; SCHOOL CHILD; STANDARD; TREATMENT DURATION; ULCERATIVE COLITIS;

ADSORPTION; ADULT; BLOOD COMPONENT REMOVAL; BLOOD VOLUME; BODY WEIGHT; COLITIS, ULCERATIVE; FEMALE; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; MONOCYTES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051997198     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00968.x     Document Type: Article

References (24)

1. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;11:S3-S12.
2. Saniabadi AR, Hanai H, Suzuki Y etal. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
3. Allison MC, Dhillon AP, Lewis WG, eds. Inflammatory Bowel Disease. London: Mosby, 1998; 9-95.
4. Shimoyama T, Sawada K, Hiwatashi N etal. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9.
5. Sakuraba A, Motoya S, Watanabe K etal. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-5.
6. Hanai H, Iida T, Takeuchi K etal. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6.
7. Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
8. Sawada K, Muto T, Shimoyama T etal. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a Leukocytapheresis column. Curr Pharm Des 2003;9:307-21.
9. Saniabadi AR, Hanai H, Sawada K etal. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci 2007;37:191-200.
10. Snimada M, Iwase H, Tsuzuki T etal. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial 2008;12:368-73.
11. Yamaji K, Onuma S, Yasuda M etal. Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers. Ther Apher Dial 2006;10:396-403.
12. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-71.
13. Tanaka T, Okanobu H, Murakami E etal. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008;40:731-6.
14. Hibi T, Sameshima Y, Sekiguchi Y etal. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7.
15. Suzuki Y, Yoshimora N, Fukuda K etal. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8.
16. Bresci G, Parisi G, Mazzoni A etal. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 2008;23:1678-82.
17. Maiden L, Takeuchi K, Baur R etal. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008;14:1413-8.
18. Muratov V, Lundahl J, Ulfgren AK etal. Downregulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504.
19. Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr Med Res Opin 2007;23:2715-28.
20. Abreu MT, Plevy S, Sands BE etal. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-88.
21. Sands BE, Sandborn WJ, Feagan B etal. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-9.
22. Hanai H, Watanabe F, Yamada M etal. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8.
23. + T-cell subsets in patients with ulcerative colitis: modified by selective leucocytapheresis. Dig Dis Sci 2007;52:2725-31.
24. Kamikozuru K, Fukunaga K, Hirota S etal. The expression profile of functional regulatory T cells, CD4(+)CD25(high+)/ forkhead box protein P3(+), in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol 2009;156:320-7.